First-in-Human trial tests revolutionary CAR-T therapy for incurable autoimmune diseases
NCT ID NCT07049081
Summary
This is an early-stage study to test the safety and initial effects of an experimental treatment called LUCAR-G79. It is for adults with severe autoimmune diseases like lupus or scleroderma that have come back or not improved with standard treatments. The treatment involves collecting and genetically modifying a patient's own immune cells (CAR-T cells) to potentially target and control their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Nantong University
NOT_YET_RECRUITINGNantong, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Zhongshan Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Soochow University
NOT_YET_RECRUITINGSuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third The People's Hospital of Bengbu
RECRUITINGBengbu, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The second Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi’an, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.